EIM
KPTI icon

Essex Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

Essex Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,720
Closed -$524K – 359
2016
Q4 		$524K Buy
+3,720
New +$503K 0.09% 244
2014
Q1 		– Sell
-2,587
Closed -$890K – 363
2013
Q4 		$890K Buy
+2,587
New +$715K 0.13% 210

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Essex Investment Management's KPTI Position: Q1 2017 in Review

Essex Investment Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2017, closing a stake of 3,720 shares — an estimated $524K sold.

Essex Investment Management first reported a position in KPTI in Q4 2013 and held it in 2 quarters. The position peaked at $890K in Q4 2013. 80 funds tracked by Wall St. Rank hold KPTI as of Q1 2017.

  • Essex Investment Management reported no remaining Karyopharm Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Essex Investment Management sold 3,720 Karyopharm Therapeutics shares in Q1 2017, an estimated $524K.
  • Essex Investment Management first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 2 quarters.
  • Essex Investment Management's Karyopharm Therapeutics position peaked at $890K in Q4 2013.
  • 80 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2017.

Based on Essex Investment Management's 13F filing for Q1 2017, filed 27 Apr 2017.